News Column

New Breast Cancer Findings from Technical University Reported (Active targeting of mesoporous silica drug carriers enhances gamma-secretase inhibitor...

August 14, 2014



New Breast Cancer Findings from Technical University Reported (Active targeting of mesoporous silica drug carriers enhances gamma-secretase inhibitor efficacy in an in vivo model for breast cancer)

By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators discuss new findings in Oncology. According to news reporting from Eindhoven, Netherlands, by NewsRx journalists, research stated, "In this article, we use an alternative cancer model for the evaluation of nanotherapy, and assess the impact of surface functionalization and active targeting of mesoporous silica nanoparticles ( MSNPs) on therapeutic efficacy in vivo. We used the chorioallantoic membrane xenograft assay to investigate the biodistribution and therapeutic efficacy of folate versus polyethyleneimine-functionalized gamma-secretase inhibitor-loaded MSNPs in breast and prostate tumor models."

The news correspondents obtained a quote from the research from Technical University, "gamma-secretase inhibitor-loaded MSNPs inhibited tumor growth in breast and prostate cancer xenografts. Folate conjugation improved the therapeutic outcome in folic acid receptor-positive breast cancer, but not in prostate cancer lacking the receptor. The results demonstrate that therapeutic efficacy is linked to cellular uptake of MSNPs as opposed to tumor accumulation, and show that MSNP-based delivery of gamma-secretase inhibitors is therapeutically effective in both breast and prostate cancer."

According to the news reporters, the research concluded: "In this article, we present a model system for a medium-to-high throughput, cost-effective, quantitative evaluation of nanoparticulate drug carriers."

For more information on this research see: Active targeting of mesoporous silica drug carriers enhances gamma-secretase inhibitor efficacy in an in vivo model for breast cancer. Nanomedicine, 2014;9(7):971-987. Nanomedicine can be contacted at: Future Medicine Ltd, Unitec House, 3RD Floor, 2 Albert Place, Finchley Central, London, N3 1QB, England. (Elsevier - www.elsevier.com; Nanomedicine - www.elsevier.com/wps/product/cws_home/703416)

Our news journalists report that additional information may be obtained by contacting R. Wittig, Technical Univ Eindhoven, Dept. of Biomed Engn, NL-2612 Eindhoven, Netherlands. Additional authors for this research include J.M. Rosenholm, E. von Haartman, J. Hemming, F. Genze, L. Bergman, T. Simmet, M. Linden and C. Sahlgren (see also Oncology).

Keywords for this news article include: Europe, Therapy, Oncology, Eindhoven, Secretase, Netherlands, Breast Cancer, Women's Health, Enzymes and Coenzymes

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Women's Health Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters